79. Assessment of the acute and subacute toxicity of Bacillus spp. on experimental animals
Main Article Content
Abstract
The study was performed to evaluate the acute and subacute toxicity tests on animals of the Bacillus spp. (B. subtilis, B. coagulans, B. clausii with concentration 1x109 CFU/mL). Acute toxicity study on Swiss mice by oral administration using the fixed dose method. A subacute toxicity study was conducted on Albino rabbits. The results of acute toxicity study showed that probiotics administered orally at a single dose up to 5000 mg/kg/day (2x1010 CFU/kg/day) did not cause toxicity, the lethal dose LD50 has not been determined. In the sub-chronic toxicity study, mild liver degeneration appeared in both the group of 1 g/kg/day and 5 g/kg/day compared to the control group. However, blood test results showed that liver function indexes (AST, ALT, GGT) and kidney function (Creatinine, Urea) were similar between the groups using the product and the control group. The difference was not statistically significant (p > 0.05). Thus, Bacillus sp. VN does not cause acute toxicity when administered orally at doses up to 5000 mg/kg. Using two dose levels of 1 and 5 g/kg/day is relatively safe in subacute toxicity.
Article Details
Keywords
Probiotics, Bacillus spp., animals
References
2. P Mastromarino, S Macchia, L Meggiorini, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clinical Microbiology and Infection. 2009; 15(1): 67-74.
3. Luca S, Andrea A, Natalia P, et al. Bacillus coagulans LMG S-24828 Impairs Candida Virulence and Protects Vaginal Epithelial Cells against Candida Infection In Vitro. Microorganisms. 2024; 12: 1634.
4. Mohsen G, Nastaran B, Zahra M, et al. Isolation and characterization of novel Bacillus strains with superior probiotic potential: comparative analysis and safety evaluation. Scientific Reports. 2024; 14: 1457.
5. Nista E C, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004; 20: 1181-1188.
6. Iryna B S, Iryna V P, Muriel D, et al. The Safety of Two Bacillus Probiotic Strains for Human Use. Dig Dis Sci. 2008; 53: 954-963.
7. Suvarna G. Lakshmi a, N. Jayanthi a, M. Saravanan, et al. Safety assesment of Bacillus clausii UBBC07, a spore forming probiotic. Toxicology Reports. 2017; 4: 62-71.
8. OECD423. OECD guideline for testing of chemicals: Acute Oral Toxicity – Acute Toxic Class Method. 2001.
9. OECD407. OECD guideline for testing of chemicals: Repeated Dose 28-Day Oral Toxicity Study in Rodents. 2008.
10. Nguyen Duy Ha, Ta Thi Ngoc Anh, Dinh Toi Chu, et al. The acute toxicity and semi-chronic toxicity of bacimix product containing two strains of Bacillus subtilis BS 304.04 and Bacillus coagulans BC 304.06 on experimental animal model. Journal of Military Pharmaco - Medicine. 2022; 7: 133-144.
11. JR. Endresa, I Qureshia, T Farber, et al. One-year chronic oral toxicity with combined reproduction toxicity study of a novel probiotic, Bacillus coagulans, as a food ingredient. Food and Chemical Toxicology. 2011; 49: 1174-1182.